Scilex Holding Company Warrant
SCLXW
About: Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.
Employees: 31
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
1.12% less ownership
Funds ownership: 1.86% [Q1] → 0.73% (-1.12%) [Q2]
29% less funds holding
Funds holding: 7 [Q1] → 5 (-2) [Q2]
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
75% less capital invested
Capital invested by funds: $39.9K [Q1] → $10.1K (-$29.8K) [Q2]
Financial journalist opinion
We haven’t received any recent news articles for SCLXW